Service de chirurgie oncologique, Centre René-Gauducheau, 44805 Nantes-Saint-Herblain, Service de gynécologie obstétrique, CHU, Angers, Service de chirurgie oncologique, Centre Alexis-Vautrin, avenue de Bourgogne, 54511 Vandœuvre-lès-Nancy cedex, Service de chirurgie oncologique, Institut Claudius-Regaud, Toulouse
Standard therapy for advanced ovarian cancer includes cytoreductive surgery associated with platin based chemotherapy. Secondary surgery for recurrent ovarian cancer remains controversial. Actually there is not randomized trial based on this question. Furthermore literature shows that patients with recurrent disease may derive a significant survival benefit from optimal debulking. The datas availables indicate that prolonged disease free interval and feasibility of complete surgical resection are the main prognosis criteria. Proper selection of patients with recurrent ovarian cancer is essential to improve the therapeutic benefit of secondary surgery. There is a large place for trials and evaluation of innovatives techniques as hyperthermic intraperitoneal chemotherapy or intraperitoneal radio-immunotherapy.